Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New spinal device aims to get fracture patients back on their feet

NCT ID NCT07301749

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a medical device called VCFix to treat broken vertebrae (spinal bones) from compression fractures. The goal is to reduce pain and improve movement in 103 adults aged 21-85 with a single recent fracture. The device is placed into the bone to restore height and stability, with follow-up over 12 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 148 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject is ≥ 21 to ≤ 85 years old. 2. Single vertebral fracture which meets all of the following criteria: * Type A fractures from AO spine classification (compression injuries); * Vertebral fracture located in the thoracic and lumbar regions of the spine * Fracture age \< 6 weeks or fractures with anatomic signs of reducibility (based on radiographic evidence as well as patient history) * Vertebral fracture shows an estimated height loss in the anterior or mid third of the vertebral body (VB) of at least 10% but not more than 60% based on radiographic evidence * Target VB has appropriate anatomy, i.e. suitable pedicle diameter, pedicle length and chord length that would allow for selection of correct implant size, as described in the IFU and based on axial MRI/CT scan before surgery 3. Subject has a NPRS back pain score of ≥5 4. Subject is a candidate for surgical intervention based on investigator opinion 5. Subject has a body Mass Index (BMI) \< 35 6. Subject is mentally capable of complying with trial protocol requirements for the duration of the study 7. Subject can understand the risks and benefits of participating in the study and is able to provide written informed consent Exclusion Criteria: 1. Neoplasms with posterior involvement and/or presence of a mass within the spinal canal 2. Non-mobile fractures (i.e., fracture is not recent (\>6 weeks), bone marrow edema or fluid or empty cleft are not visible in radiographic imaging, or fracture mode does not allow for fracture reduction in craniocaudal direction). 3. Spondylolisthesis \> Grade 1 at target vertebral body(s) 4. Local kyphotic angle \> 30° 5. Pre-existing vertebral fracture prior to the index fracture 6. Subjects that require anterior stabilization of the index fracture 7. Fracture to the pedicle based on radiographic evaluation 8. Spinal cord compression or canal compromise requiring decompression 9. Severe back pain due to causes other than acute fracture with NPRS score\>5 10. The subject has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis) 11. Pain due to any other condition that requires daily narcotic (opiates or opioids) medication 12. Pre-existing neurological deficit, radiculopathy or myelopathy 13. Pre-existing condition or significant co-morbidity: * Uncontrolled diabetes (HbA1c \>8%) * Severe cardiopulmonary deficiencies * Any other condition that would impact study outcome in the opinion of the investigator 14. Contraindications to both MRI and radionuclide bone scan 15. Concurrent participation in another clinical study which could potentially interfere with the outcome of this study. 16. A life expectancy less than the study duration or undergoing palliative care 17. Subject non-ambulatory prior to fracture 18. Allergy to any components of the device/instruments used during the procedure 19. Active or incompletely treated infection of the vertebral column or active systemic infection, including unresolved urinary tract infection 20. Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfecta, Paget's disease, etc.) 21. Any evidence of alcohol or drug abuse. 22. Ongoing long-term steroid therapy (steroid dose ≥30 mg /day for \>3 months) 23. The subject is currently on anti-cancer therapy or anti-HIV therapy 24. Pregnancy or subjects with child-bearing potential that are unwilling to use contraception throughout the study duration

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vertebral compression fracture are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    3 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Métropole de Savoie

    NOT_YET_RECRUITING

    Chambéry, France

    Contact Email: •••••@•••••

  • Krankenhaus Mechernich

    RECRUITING

    Mechernich, Germany

  • Wilhelmsburger Krankenhaus Groß-Sand

    RECRUITING

    Hamburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.